Abarelix (trade name Plenaxis) is an injectable gonadotropin-releasing hormone
antagonist (GnRH antagonist). It is primarily used in oncology to reduce the ...
Learn about Plenaxis (Abarelix) may treat, uses, dosage, side effects, drug
interactions, warnings, patient labeling, reviews, and related medications.
Abarelix reduces the amount of testosterone produced in the body. Abarelix is
used in the palliative treatment of advanced prostate cancer. Abarelix may also
Abarelix | C72H95ClN14O14 | CID 16131215 - structure, chemical names,
physical and chemical properties, classification, patents, literature, biological ...
Class: Hormonal therapy. Generic Name: Abarelix Trade Name: Plenaxis™. For
which conditions is this drug approved? Abarelix is FDA approved for the ...
Jun 13, 2005 ... Name, Abarelix. Accession Number, DB00106 (BTD00051, BIOD00051). Type,
Biotech. Groups, Approved, Investigational, Withdrawn.
(abarelix for injectable suspension). WARNING. Immediate-onset systemic
allergic reactions, some resulting in hypotension and syncope, have occurred
Oct 23, 2015 ... Abarelix|Plenaxis<sup>®</sup>|50|2008. StartServiceArzneistoffeAbarelix|Plenaxis|50|2008 ·
Hier klicken! NEUE ARZNEISTOFFE ...
ABARELIX (Plenaxis™) was used to treat advanced prostate cancer when other
treatments could not be used or were refused. Abarelix was available only from ...
US studies compared abarelix with leuprolide alone or with bicalutamide over 3
and 6 months, respectively, while a 48-week European trial compared abarelix ...